Oncocyte Corporation — Form 10-Q Summary
Filing identity: The supplied filing is Oncocyte Corporation’s 10-Q, not a filing under the metadata name “Insight Molecular Diagnostics Inc.” It covers the quarter and nine months ended September 30, 2022; statements are unaudited. Dollar amounts below are in millions unless stated otherwise.
Business context and reporting period
Oncocyte develops and commercializes molecular diagnostic tests and provides pharmaceutical services. Its commercial portfolio includes DetermaRx, a lung-cancer treatment stratification test, and Pharma Services; DetermaIO, DetermaTx, DetermaMx, DetermaCNI and VitaGraft were in development or commercialization planning. The company reported one operating segment.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $1.017 | $0.984 | $4.508 | $4.138 |
| Gross profit (loss) | $(1.174) | $(0.866) | $(2.021) | $(1.181) |
| Operating loss | $(9.221) | $(13.604) | $(27.678) | $(38.532) |
| Net loss | $(9.333) | $(13.800) | $(27.924) | $(28.212) |
| Net loss per share, basic and diluted | $(0.08) | $(0.15) | $(0.26) | $(0.32) |
Revenue grew 3% in Q3 and 9% year to date. DetermaRx revenue rose 136% in Q3 to $0.950 million and 68% year to date to $2.784 million. Pharma Services revenue fell 76% in Q3 to $0.067 million and 29% year to date to $0.684 million; licensing revenue was nil in Q3 and declined 31% year to date to $1.040 million. DetermaRx accounted for 93% of Q3 revenue and 62% of nine-month revenue.
Gross margins remained negative: approximately (115)% in Q3 and (45)% for the first nine months, based on reported revenue and gross loss. Cost of revenue, including acquired-intangible amortization, exceeded revenue in both periods. R&D and sales and marketing expenses increased year over year, while nine-month G&A declined.
For the nine months, net cash used in operating activities was $35.920 million; investing activities used $3.538 million, principally for equipment and construction; financing activities provided $35.906 million. Cash and cash equivalents were $32.053 million at September 30, 2022, plus $1.700 million of restricted cash and $0.419 million in marketable equity securities. Accumulated deficit was $215.698 million. The company reported no remaining bank-loan principal; lease liabilities totaled approximately $3.762 million. Contingent consideration liabilities were $59.524 million.
Material changes versus prior comparable periods
- Operating loss improved year over year, but the nine-month net loss was nearly unchanged. A $17.157 million noncash gain from a reduction in contingent consideration fair value materially improved reported operating results; the comparable 2021 period recorded a $2.260 million loss.
- Q3 revenue growth was driven by DetermaRx, partly offset by lower Pharma Services and licensing revenue. Management attributed the lower licensing revenue in part to the end of service-agreement revenue.
- Nine-month R&D rose 67% to $15.123 million, and sales and marketing rose 37% to $10.764 million. The company cited development programs, clinical trials, and increased personnel and commercialization activity.
- Common shares outstanding increased from 92.232 million at December 31, 2021 to 118.619 million at September 30, 2022. The April 2022 equity-and-warrant offering and Series A preferred financing raised capital but introduced potential dilution and redemption obligations.
Outlook, commentary, risks and unusual items
- Management said cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months from issuance of the financial statements, but stated that continued operations depend on executing the business plan, generating revenue and raising additional capital. No numerical revenue or earnings guidance was provided.
- The company committed in August 2022 to eliminate 14 positions, tighten expense controls and cease non-core activities. It recorded $0.7 million of severance expense and accrued $0.5 million related to the reduction at quarter-end. Management also described potential spending controls, including limiting capital spending and reducing external resources.
- On August 9, 2022, Nasdaq notified the company that its share price had failed the $1.00 minimum bid requirement. The initial compliance period ran through February 6, 2023; failure to regain compliance could result in delisting and impair access to financing.
- Series A preferred stock carries a 6% cumulative dividend, potential cash redemption (including on April 8, 2024, subject to the terms), and an $8 million minimum-cash covenant. The filing reports 5,882.4 preferred shares outstanding at quarter-end and describes a second $5 million tranche; investors should verify its closing status after quarter-end.
- COVID-19-related delays to surgeries and clinical trials, payer coverage and reimbursement uncertainty, dependence on additional financing, customer and revenue concentration, and potential impairment of acquired intangible assets were identified as risks. Medicare Advantage represented 86% of accounts receivable at September 30, 2022.
- The $17.157 million contingent-consideration fair-value gain was based on revised assumptions about discount rates and timing of possible payouts, rather than operating cash generation. No material litigation was reported, and the filing disclosed no subsequent events.
Investor facts to verify
- Confirm the filing’s issuer identity and resolve the mismatch with the supplied company metadata.
- Assess operating cash burn, available liquidity, and whether the stated 12-month runway assumptions remain valid.
- Verify progress on Nasdaq bid-price compliance and the effect of any listing status change on capital access.
- Review the Series A second-tranche closing, redemption and cash-covenant terms, and the potential dilution from preferred stock and warrants.
- Track DetermaRx test volume, payer collections and reimbursement coverage, alongside the path to positive gross margins and revenue diversification.
- Evaluate the assumptions behind contingent consideration revaluations and the carrying values of acquired intangible assets.